Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StockNews.com 

United Therapeutics diskutieren

United Therapeutics

WKN: 923818 / Symbol: UTHR / Name: Utd Therapeut / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /

327,60 €
4,90 %

Einschätzung Buy
Rendite (%) 11,89 %
Kursziel 341,51
Veränderung
Endet am 08.07.25

United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at UBS Group AG from $300.00 to $370.00. They now have a "buy" rating on the stock.
Ratings data for UTHR provided by MarketBeat

United Therapeutics Co. (NASDAQ: UTHR) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for UTHR provided by MarketBeat

Einschätzung Buy
Rendite (%) 5,41 %
Kursziel 368,56
Veränderung
Endet am 25.07.25

United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at HC Wainwright from $300.00 to $400.00. They now have a "buy" rating on the stock.
Ratings data for UTHR provided by MarketBeat

Einschätzung Sell
Rendite (%) 9,02 %
Kursziel 259,28
Veränderung
Endet am 01.08.25

United Therapeutics Co. (NASDAQ: UTHR) had its price target lowered by analysts at Bank of America Co. from $303.00 to $280.00. They now have an "underperform" rating on the stock.
Ratings data for UTHR provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,57 %
Kursziel 370,24
Veränderung
Endet am 01.08.25

United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $400.00 price target on the stock.
Ratings data for UTHR provided by MarketBeat

United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for UTHR provided by MarketBeat

Einschätzung Buy
Rendite (%) 4,30 %
Kursziel 341,89
Veränderung
Endet am 20.08.25

United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at Wells Fargo & Company from $350.00 to $380.00. They now have an "overweight" rating on the stock.
Ratings data for UTHR provided by MarketBeat

Einschätzung Buy
Rendite (%) 0,86 %
Kursziel 517,04
Veränderung
Endet am 28.08.25

United Therapeutics Co. (NASDAQ: UTHR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $400.00 to $575.00. They now have an "outperform" rating on the stock.
Ratings data for UTHR provided by MarketBeat